Washington, D.C. (February 10, 2022) – The Global Alzheimer’s Platform Foundation® (GAP) announced that MedVadis Research has joined its network of more than 100 global clinical trial sites (GAP-Net), a team of leading academic and private research sites collaborating to accelerate the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials and improving equity in clinical trial recruitment around the world. As a GAP-Net member, MedVadis Research will continue to have measurable impact on its local community as they conduct research studies of new treatments and therapies for Alzheimer’s disease affecting the Boston community, while accessing expertise from other sites to maximize opportunities for people living with Alzheimer’s and Parkinson’s to participate in research.
“We welcome MedVadis Research into the GAP Network. For over 25 years, they have been conducting important research in the greater Boston area, and will now be able to increase the availability of Alzheimer's clinical trials in this growing market,” said GAP President John Dwyer. “We commend their commitment to enrolling volunteers from diverse backgrounds, helping to ensure that future treatments are sensitive and specific to all people.”
As Massachusetts continues to face rising rates of Alzheimer’s, clinical intervention is imperative. By 2025, it is projected that 150,000 Massachusetts residents will be diagnosed with Alzheimer’s, a 15% increase from cases in 2018.
“We’re honored to join GAP’s network of clinical trial sites,” said David DiBenedetto, M.D., General Director and Principal Investigator at MedVadis Research. “While advancements have been made in Alzheimer’s treatments, currently there is no cure for the disease. Current research efforts will lead us to a better understanding of the fundamental causes of Alzheimer’s disease. The more we know about how and why the disease manifests, the faster therapies can be developed to treat it. We see a lot of hope for finding ways to delay the onset of symptoms or even prevent Alzheimer’s in the first place.”
Since its founding in 1996, MedVadis Research has facilitated approximately 400 clinical trials, including around 3,000 participants in clinical research. Now as part of GAP-Net, MedVadis Research will continue to bring a high level of care, innovation, and equity to the Boston community.
To learn more about any of the clinical trials at MedVadis, including Alzheimer’s clinical trials, please visit https://medvadis.com, email email@example.com or call (781) 373-2940.
About MedVadis Research
MedVadis Research is an independent clinical trial research center in Massachusetts dedicated to advancing and discovering new medical treatments. Founded in 1996, the center has conducted hundreds of clinical trials and research studies focused on various conditions, including migraine headache, Alzheimer’s disease, Parkinson’s disease, chronic low-back pain, osteoarthritis, painful diabetic neuropathy, fibromyalgia, asthma, hypertension, irritable bowel disease, and diabetes. MedVadis is also a member of the GAP-Net network of major research sites working with the Global Alzheimer’s Platform Foundation to further Alzheimer’s and dementia research. Clinical trials run throughout the year. To learn more or sign up to participate, visit: https://medvadis.com.
About the Global Alzheimer’s Platform Foundation® (GAP)
The Global Alzheimer’s Platform Foundation® (GAP) is a person-centric nonprofit dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Research centers across the US, Canada, and Europe are part of the growing GAP Network (GAP-Net). GAP supports GAP-Net research centers by assisting with study start up and recruitment activities, promoting diversity in research studies, and offering national programs that champion brain health and the citizen scientists who make research possible.
On Behalf of GAP
On Behalf of MedVadis